- AU$135.09m
- AU$96.64m
- AU$5.91m
Brief: Dimerix Records FY Loss Attributable A$10.5 Mln
Brief: Dimerix Says It Entered Agreement With Australian Centre For Accelerating Diabetes Innovations
Brief: Dimerix Says FDA Ind Approval For Phase 3 Study Of Dmx-200 In FSGS
Australia Stock Exchange release from DIMERIX : Dimerix Receives A$3.7M R&D Tax Incentive Rebate
Australia Stock Exchange release from DIMERIX : PRE_NR Ends: 09:16:12
Australia Stock Exchange release from DIMERIX : Investor Presentation
Australia Stock Exchange release from DIMERIX : Dimerix Investor Call and Presentation
Australia Stock Exchange release from DIMERIX : PRE_NR Ends: 09:35:21
Australia Stock Exchange release from DIMERIX : DSMB Change to REMAP-CAP COVID-19 Study
Australia Stock Exchange release from DIMERIX : Investor Presentation
Australia Stock Exchange release from DIMERIX : PRE_NR Ends: 09:35:15
Australia Stock Exchange release from DIMERIX : Half-Year Financial Report & Appendix 4D - 31 December 2021
Australia Stock Exchange release from DIMERIX : Dimerix Appoints Chief Medical Officer
Australia's Dimerix rises on Denmark regulatory nod for clinical trial
Australia Stock Exchange release from DIMERIX : First Regulatory Approval in Europe for DMX-200 FSGS Study
Australia Stock Exchange release from DIMERIX : PRE_NR Ends: 12:01:49
Australia Stock Exchange release from DIMERIX : PRE_NR Ends: 09:06:33
Australia Stock Exchange release from DIMERIX : Quarterly Appendix 4C and Activities Report
Australia's Dimerix climbs on patient dosing to test COVID-19 drug in India